✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Neuland Laboratories Ltd.

NEULANDLAB

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹16,733 Cr.
P/E
95.00

Neuland Laboratories Ltd.

  • Neuland Laboratories
  • Gufic Biosciences
  • Alivus Life Sciences
  • TJI Pharma - Small Cap
FAQs on Neuland Laboratories Ltd. Shareprice

Neuland Laboratories has given better returns compared to its competitors.
Neuland Laboratories has grown at ~94.34% over the last 2yrs while peers have grown at a median rate of 49.51%

Yes, Neuland Laboratories is expensive.
Latest PE of Neuland Laboratories is 95.0, while 3 year average PE is 34.32.
Also latest EV/EBITDA of Neuland Laboratories is 70.87 while 3yr average is 21.65.

View FAQ's On Business
Growth Table
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Balance Sheet
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Cash Flow
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Quarterly Results
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Neuland Laboratories Ltd. Financials

Balance sheet of Neuland Laboratories is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Neuland Laboratories is decreasing.
Latest net debt of Neuland Laboratories is -₹381.59 Crs as of Mar-25.
This is less than Mar-24 when it was -₹151.04 Crs.

No, profit is decreasing.
The profit of Neuland Laboratories is ₹176 Crs for TTM, ₹260 Crs for Mar 2025 and ₹300 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Neuland Laboratories latest dividend payout ratio is 5.92% and 3yr average dividend payout ratio is 6.58%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech